Genomic diagnostics company Veracyte Inc (Nasdaq:VCYT) stated on Tuesday that it recorded a net loss of USD0.7m for the third quarter ended 30 September 2019.

This marks an improvement of improvement of 84% from net loss of USD4.47m the same prior year quarter.

Net loss per share of USD0.02 was recorded for the third quarter ended 30 September 2019, a rise of 83% from net loss per share of 0.12 in the comparable year quarter.

Revenue of USD31.0m was generated for the third quarter of 2019, up 32% over the revenues of USD23.4m in the third quarter of 2018.

Research and development expenses of USD3.6m and USD3.4m were announced for the third quarters of 2019 and 2018 respectively.